{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:18:05Z","timestamp":1782278285758,"version":"3.54.5"},"reference-count":29,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Leptomeningeal disease (LMD) is a clinical sequela of central nervous system metastasis involving the cerebrospinal fluid (CSF), often seen in late-stage solid tumors. It has a grave prognosis without urgent treatment. Standard of care methodologies to diagnose LMD include CSF cytology, magnetic resonance imaging, and clinical evaluation. These methods offer limited sensitivity and specificity for the evaluation of LMD. Here, we describe the analytic performance characteristics of a microfluidic-based tumor cell enrichment and detection assay optimized to detect epithelial cells in CSF using both contrived samples as well as CSF from patients having suspected or confirmed LMD from carcinomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To demonstrate the feasibility of using a microfluidic, multi-antibody cell capture assay to identify and quantify tumor cells in CSF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>An artificial CSF solution was spiked with 34 different human carcinoma cell lines at different concentrations and assayed for the ability to detect tumor cells to assess analytic accuracy. Two cell lines were selected to assess linearity, intra-assay precision, interinstrument precision, and sample stability. Clinical verification was performed on 65 CSF specimens from patients. Parameters assessed included the number of tumor cells, coefficient of variation percentage, and percentage of tumor cell capture (TCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Among contrived samples, average tumor cell capture ranged from 50% to 82% (261 of 522; 436 of 531), and coefficients of variation ranged from 7% to 67%. The cell capture assay demonstrated a sensitivity of 92% and a specificity of 95% among clinical samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>This assay demonstrated the ability to detect and enumerate epithelial cells in contrived and clinical specimens in an accurate and reproducible fashion. The use of cell capture assays in CSF may be useful as a sensitive test for the diagnosis and longitudinal monitoring of LMD from solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2023-0295-oa","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T20:00:10Z","timestamp":1716753610000},"page":"242-252","source":"Crossref","is-referenced-by-count":4,"title":["A Microfluidic, Multi-Antibody Cell Capture Method to Evaluate Tumor Cells in Cerebrospinal Fluid in Patients With Suspected Leptomeningeal Metastases"],"prefix":"10.5858","volume":"149","author":[{"given":"Nathan T.","family":"Sweed","sequence":"first","affiliation":[{"name":"From the Clinical Department (Sweed, Blouw, Dugan, Naluz, Mayer) and Research and Development (Hsiao, Pircher, Fisher), Biocept, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Ching","family":"Hsiao","sequence":"additional","affiliation":[{"name":"From the Clinical Department (Sweed, Blouw, Dugan, Naluz, Mayer) and Research and Development (Hsiao, Pircher, Fisher), Biocept, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Blouw","sequence":"additional","affiliation":[{"name":"From the Clinical Department (Sweed, Blouw, Dugan, Naluz, Mayer) and Research and Development (Hsiao, Pircher, Fisher), Biocept, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony J.","family":"Pircher","sequence":"additional","affiliation":[{"name":"From the Clinical Department (Sweed, Blouw, Dugan, Naluz, Mayer) and Research and Development (Hsiao, Pircher, Fisher), Biocept, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Fisher","sequence":"additional","affiliation":[{"name":"From the Clinical Department (Sweed, Blouw, Dugan, Naluz, Mayer) and Research and Development (Hsiao, Pircher, Fisher), Biocept, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina Rose","family":"Naluz","sequence":"additional","affiliation":[{"name":"From the Clinical Department (Sweed, Blouw, Dugan, Naluz, Mayer) and Research and Development (Hsiao, Pircher, Fisher), Biocept, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Ann","family":"Mayer","sequence":"additional","affiliation":[{"name":"From the Clinical Department (Sweed, Blouw, Dugan, Naluz, Mayer) and Research and Development (Hsiao, Pircher, Fisher), Biocept, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Dugan","sequence":"additional","affiliation":[{"name":"From the Clinical Department (Sweed, Blouw, Dugan, Naluz, Mayer) and Research and Development (Hsiao, Pircher, Fisher), Biocept, Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Neuro-Oncology, Pacific Neuroscience Institute and Providence Saint John\u2019 Cancer Institute, Santa Monica, California (Sharma, Carrillo, Kesari)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Carrillo","sequence":"additional","affiliation":[{"name":"Neuro-Oncology, Pacific Neuroscience Institute and Providence Saint John\u2019 Cancer Institute, Santa Monica, California (Sharma, Carrillo, Kesari)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[{"name":"Neuro-Oncology, Pacific Neuroscience Institute and Providence Saint John\u2019 Cancer Institute, Santa Monica, California (Sharma, Carrillo, Kesari)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"issue":"5","key":"2025022423522766200_i1543-2165-149-3-242-b01","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/neuonc\/noac249","article-title":"Incidence proportion and prognosis of leptomeningeal disease among patients with breast versus non-breast primaries","volume":"25","author":"Lamba","year":"2023","journal-title":"Neuro Oncol"},{"issue":"12","key":"2025022423522766200_i1543-2165-149-3-242-b02","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/sj.leu.2401963","article-title":"Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982\u20131995","volume":"14","author":"Conter","year":"2000","journal-title":"Leukemia"},{"issue":"12","key":"2025022423522766200_i1543-2165-149-3-242-b03","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/sj.leu.2401939","article-title":"Children\u2019s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983\u20131995","volume":"14","author":"Gaynon","year":"2000","journal-title":"Leukemia"},{"issue":"3","key":"2025022423522766200_i1543-2165-149-3-242-b04","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/cancers13030438","article-title":"Cerebrospinal fluid biomarkers in childhood leukemias","volume":"13","author":"Ikonomidou","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2025022423522766200_i1543-2165-149-3-242-b05","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2003.10.032","article-title":"Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia","volume":"21","author":"Pui","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025022423522766200_i1543-2165-149-3-242-b06","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/0-387-24199-X_2","article-title":"Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging","volume":"125","author":"Enting","year":"2005","journal-title":"Cancer Treat Res"},{"issue":"7","key":"2025022423522766200_i1543-2165-149-3-242-b07","first-page":"535","article-title":"A word of caution in the use of neuron-specific enolase expression in tumor diagnosis","volume":"108","author":"Dranoff","year":"1984","journal-title":"Arch Pathol Lab Med"},{"issue":"42","key":"2025022423522766200_i1543-2165-149-3-242-b08","doi-asserted-by":"crossref","first-page":"73312","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: current diagnostic and therapeutic strategies","volume":"8","author":"Nayar","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"2025022423522766200_i1543-2165-149-3-242-b09","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2004.05.008","article-title":"Leptomeningeal metastasis: survival and prognostic factors in 155 patients","volume":"223","author":"Herrlinger","year":"2004","journal-title":"J Neurol Sci"},{"issue":"4","key":"2025022423522766200_i1543-2165-149-3-242-b10","first-page":"362","article-title":"Leptomeningeal disease and the evolving role of molecular targeted therapy and immunotherapy","volume":"17","author":"Thomas","year":"2017","journal-title":"Ochsner J"},{"issue":"9","key":"2025022423522766200_i1543-2165-149-3-242-b11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(10)70034-6","article-title":"Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours","volume":"11","author":"Beauchesne","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025022423522766200_i1543-2165-149-3-242-b12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nec.2010.08.006","article-title":"Leptomeningeal disease","volume":"22","author":"Groves","year":"2011","journal-title":"Neurosurg Clin N Am"},{"issue":"4","key":"2025022423522766200_i1543-2165-149-3-242-b13","first-page":"S265","article-title":"Carcinomatous meningitis: leptomeningeal metastases in solid tumors","volume":"4(Suppl","author":"Le Rhun","year":"2013","journal-title":"Surg Neurol Int"},{"key":"2025022423522766200_i1543-2165-149-3-242-b14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-811161-1.00013-X","article-title":"Leptomeningeal metastasis","volume":"149","author":"Taillibert","year":"2018","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"2025022423522766200_i1543-2165-149-3-242-b15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.21037\/apm-20-973","article-title":"An overview of leptomeningeal disease","volume":"10","author":"Nguyen","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"1","key":"2025022423522766200_i1543-2165-149-3-242-b16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines\u00ae insights: central nervous system cancers, version 2.2022","volume":"21","author":"Horbinski","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2025022423522766200_i1543-2165-149-3-242-b17","doi-asserted-by":"crossref","first-page":"800053","DOI":"10.3389\/fonc.2021.800053","article-title":"Challenges and advances in diagnosis and treatment of leptomeningeal disease (LMD)","volume":"11","author":"Ferguson","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"2025022423522766200_i1543-2165-149-3-242-b18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro Oncol"},{"key":"2025022423522766200_i1543-2165-149-3-242-b19","doi-asserted-by":"crossref","first-page":"902664","DOI":"10.3389\/fonc.2022.902664","article-title":"EGFR amplification is a putative resistance mechanism for NSCLC-LM patients with TKI therapy and is associated with poor outcome","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"2025022423522766200_i1543-2165-149-3-242-b20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000487070","article-title":"Assessment of the utility of cytology and flow cytometry of cerebrospinal fluid samples in clinical practice","volume":"62","author":"Nam","year":"2018","journal-title":"Acta Cytol"},{"issue":"2","key":"2025022423522766200_i1543-2165-149-3-242-b21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10549-015-3610-1","article-title":"Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer","volume":"154","author":"Lee","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2025022423522766200_i1543-2165-149-3-242-b22","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/neuonc\/nox066","article-title":"Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors","volume":"19","author":"Lin","year":"2017","journal-title":"Neuro Oncol"},{"issue":"17","key":"2025022423522766200_i1543-2165-149-3-242-b23","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1212\/WNL.0b013e31828f183f","article-title":"Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors","volume":"80","author":"Nayak","year":"2013","journal-title":"Neurology"},{"key":"2025022423522766200_i1543-2165-149-3-242-b24","first-page":"1107","volume-title":"Roberts and Hedges\u2019 Clinical Procedures in Emergency Medicine and Acute Care","author":"Euerle","year":"2019","edition":"7th ed"},{"key":"2025022423522766200_i1543-2165-149-3-242-b25","volume-title":"Youmans and Winn Neurological Surgery","author":"Shunting","year":"2017"},{"key":"2025022423522766200_i1543-2165-149-3-242-b26","volume-title":"Goldman-Cecil Medicine","author":"Deluca","year":"2020","edition":"26th ed"},{"key":"2025022423522766200_i1543-2165-149-3-242-b27","first-page":"441","volume-title":"Laboratory Tests and Diagnostic Procedures","author":"Chernecky","year":"2013","edition":"6th ed"},{"issue":"9","key":"2025022423522766200_i1543-2165-149-3-242-b28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s004150050459","article-title":"The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis","volume":"246","author":"Straathof","year":"1999","journal-title":"J Neurol"},{"issue":"2","key":"2025022423522766200_i1543-2165-149-3-242-b29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","article-title":"Quantitative proteomics of the cancer cell line encyclopedia","volume":"180","author":"Nusinow","year":"2020","journal-title":"Cell"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/3\/242\/3489458\/i1543-2165-149-3-242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/3\/242\/3489458\/i1543-2165-149-3-242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:41:44Z","timestamp":1764790904000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/3\/article-p242.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,27]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2023-0295-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}